Astellas/Cardiome’s Vernakalant Wins Advisory Committee Approval In 6-2 Vote
This article was originally published in The Pink Sheet Daily
Executive Summary
Antiarrhythmic’s well-characterized safety profile is a “clear differentiator from other pharmacological therapies,” Astellas exec tells “The Pink Sheet” DAILY.
You may also be interested in...
Cardiome/Astellas Schedule Kynapid Meeting With FDA
Meanwhile, Astellas yanks its Canadian new drug submission for the atrial fibrillation candidate to align its North American regulatory strategy.
Cardiome/Astellas Schedule Kynapid Meeting With FDA
Meanwhile, Astellas yanks its Canadian new drug submission for the atrial fibrillation candidate to align its North American regulatory strategy.
Astellas/Cardiome’s Kynapid “Approvable”
FDA wants more safety data on IV vernakalant.